Director, Search & Evaluation Early TA Lead (CVR and Haem)

Darum lohnt es sich

Embedded within each Therapeutic Area Leadership Team (TALT), these leaders will identify and advance high-potential assets from preclinical through Phase 1 clinical stages, shape early partnering strategies, and drive transactions in collaboration with Business Development /ppWe have a hybrid office/home working model.

NPO meetings are strategic checkpoints where cross-functional teams review potential assets identified by Search and decide whether to advance them for further due diligence and deal negotiations /p /lilipDevelop and execute early partnering strategies, including onboarding approaches and competitive positioning for priority assets. /p /lilipDrive cross-functional due diligence for each opportunity, coordinating scientific, clinical, regulatory, and commercial assessments to inform governance decisions. /p /lilipTransaction Execution: Partner closely with BD and Regional Ecosystem Leads to advance high-priority opportunities through negotiation and deal close, ensuring seamless handoff and execution /p /lilipRepresent the TA externally, leading sourcing activities at specialized conferences and cultivating relationships with biotech, academia, and investment communities. /p /lipbQualifications /bbExperience /bbRequirements /b /plipSignificant tenure in biopharma with significant experience in external innovation, search evaluation, or business development. /p /lilipAdvanced degree required (PhD, MD, or equivalent). /p /lilipMust have Deep scientific expertise in Hematology or Cardiovascular/Renal therapeutic areas. /p /lilipProven track record of leading due diligence and closing early-stage deals. /p /lilipStrong network within biotech, academia, and pharma BD organizations. /p /lippbbAbout CSL Behring /b /b /p /ppCSL Behring is a global biotherapeutics leader driven by our promise to save lives.

Our parent company, CSL, headquartered in Melbourne, Australia, employs 32,000 people, and delivers its lifesaving therapies to people in more than 100 countries. /ppTo learn more about CSL, CSL Behring, CSL Seqirus and CSL Vifor visit and CSL Plasma at . /ppbOur Benefits /b /p pTwo Directors of Search Evaluation to lead strategic sourcing and evaluation of external innovation opportunities in Hematology, and Cardiovascular/Renal therapeutic areas.

The position will be based in Zurich (preferred) or Maidenhead, UK, with significant business travel /ppbMain /bbResponsibilities /bbAccountabilities /b /plipServe as the senior Early SE leader within the TALT, influencing therapeutic strategy and ensuring external innovation priorities are integrated into portfolio planning. /p /lilipLead proactive sourcing and scouting efforts for preclinical and Phase 1 assets, building a robust pipeline of opportunities aligned with TA strategy. /p /lilipCo-lead internal meetings (with Late Search Lead) focused on evaluating and prioritizing New Product Opportunities (NPOs) within each CSL’s therapeutic areas.

Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.

We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives. /ppbr/CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma.